STAAR Surgical (NASDAQ:STAA) Downgraded by William Blair to “Market Perform”

William Blair lowered shares of STAAR Surgical (NASDAQ:STAA) from an outperform rating to a market perform rating in a research note released on Wednesday, MarketBeat Ratings reports.

Several other analysts have also recently commented on STAA. Stephens upgraded shares of STAAR Surgical to a “hold” rating in a research note on Monday, December 2nd. Needham & Company LLC reiterated a “hold” rating on shares of STAAR Surgical in a research report on Tuesday, January 7th. Finally, Canaccord Genuity Group reduced their price objective on STAAR Surgical from $31.00 to $28.00 and set a “hold” rating on the stock in a research note on Monday, December 9th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and one has given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $28.43.

STAAR Surgical Price Performance

STAAR Surgical stock opened at $16.48 on Wednesday. The firm’s 50 day moving average price is $23.75 and its 200-day moving average price is $29.24. STAAR Surgical has a 1 year low of $13.50 and a 1 year high of $52.68. The stock has a market cap of $812.13 million, a P/E ratio of 37.45 and a beta of 0.62.

Insider Buying and Selling at STAAR Surgical

In other news, major shareholder Broadwood Partners, L.P. acquired 8,221 shares of the business’s stock in a transaction on Thursday, January 16th. The shares were acquired at an average price of $21.50 per share, for a total transaction of $176,751.50. Following the completion of the transaction, the insider now directly owns 10,878,007 shares of the company’s stock, valued at approximately $233,877,150.50. The trade was a 0.08 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have purchased a total of 105,876 shares of company stock worth $2,487,168 over the last ninety days. Company insiders own 1.00% of the company’s stock.

Institutional Investors Weigh In On STAAR Surgical

Several institutional investors have recently made changes to their positions in the company. WINTON GROUP Ltd raised its position in STAAR Surgical by 41.0% in the 4th quarter. WINTON GROUP Ltd now owns 42,964 shares of the medical instruments supplier’s stock worth $1,044,000 after purchasing an additional 12,496 shares during the period. Vanguard Group Inc. raised its holdings in shares of STAAR Surgical by 5.8% in the fourth quarter. Vanguard Group Inc. now owns 5,855,570 shares of the medical instruments supplier’s stock worth $142,232,000 after buying an additional 319,441 shares during the period. LPL Financial LLC lifted its stake in shares of STAAR Surgical by 45.3% during the 4th quarter. LPL Financial LLC now owns 15,994 shares of the medical instruments supplier’s stock worth $388,000 after acquiring an additional 4,989 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new position in STAAR Surgical during the 4th quarter valued at $180,000. Finally, American Century Companies Inc. grew its position in STAAR Surgical by 70.0% in the 4th quarter. American Century Companies Inc. now owns 13,256 shares of the medical instruments supplier’s stock valued at $322,000 after acquiring an additional 5,457 shares during the last quarter. Institutional investors own 96.70% of the company’s stock.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.